Prophylactic 2-week glecaprevir/pibrentasvir in hepatitis C positive-to-negative kidney transplantation
Nephrology Dialysis Transplantation · 2025
DOI: 10.1093/ndt/gfae271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Rebecca A Dieter und 8 weiteren Autor:innen. Beteiligte Einrichtung: NYU Langone Health, Transplant Institute, New York, NY, USA. Hauptthemen laut MEDLINE: Benzimidazoles, Kidney Transplantation, Sulfonamides, Quinoxalines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIH HHS, AbbVie.
Abstract (Originalsprache)
Background and hypothesis Hepatitis C virus (HCV) positive-to-negative kidney transplants require direct-acting antiviral therapy, but the optimal timing and duration remain unclear. We hypothesized that a 14-day prophylactic course of glecaprevir/pibrentasvir 300/120 mg (GLE/PIB) would be safe and effective at treating donor-derived HCV viremia.
Methods
This was a prospective, single-center, single-arm, open-label pilot study. Twenty adult HCV-negative recipients of HCV nucleic acid amplification test positive deceased-donor kidneys (HCV positive-to-negative) received a 14-day course of GLE/PIB, with the first dose pretransplant. HCV RNA viral load (VL) was monitored on postoperative days (POD) 1, 3, 7, and 13. If VL was undetectable on POD 13, GLE/PIB was stopped, and if detectable, GLE/PIB was continued to complete an 8-week course. Surveillance monitoring continued after treatment to ensure sustained viral response (SVR). The primary outcome was efficacy of 14-day prophylactic GLE/PIB. Secondary outcomes included patient and allograft survival, the incidence, timing, and clearance of HCV viremia, and safety events.
Results
Seven out of 20 subjects (35%) never developed detectable HCV viremia. Only one subject had a detectable, but nonquantifiable, VL on POD 13 and completed an 8-week course. All subjects achieved SVR 12 weeks post-treatment with no relapses through 1-year follow-up. Mean time to undetectable HCV RNA VL was 10.5 (±4.7) days and mean peak VL was 371 (±715) copies/mL. Six-month and 1-year patient and allograft survival were 100% and 95%.
Conclusion
A 14-day course of prophylactic GLE/PIB is safe and effective for HCV positive-to-negative kidney transplants and may prevent HCV transmission or significantly reduce the VL for those with detectable transmission, allowing rapid clearance within 2 weeks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NYU Langone Health, Transplant Institute, New York, NY, USA.
- Psychology Department, University of La Verne, La Verne, Laverne, CA, USA.
- NYU Langone Health, Grossman School of Medicine, New York, NY, USA.
ORCID-Profile: Ian S Jaffe
Förderung
- NCATS NIH HHS
- NIH HHS
- AbbVie
- National Center for Advancing Translational Sciences
- National Institutes of Health
Zitieren
APA
Dieter, R. A., Mattoo, A., Hotchkis, P., Jaffe, I. S., Weldon, E. P., Berger, J. C., Ali, N. M., Montgomery, R. A., & Lonze, B. E. (2025). Prophylactic 2-week glecaprevir/pibrentasvir in hepatitis C positive-to-negative kidney transplantation. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae271
Vancouver
Dieter RA, Mattoo A, Hotchkis P, Jaffe IS, Weldon EP, Berger JC, et al. Prophylactic 2-week glecaprevir/pibrentasvir in hepatitis C positive-to-negative kidney transplantation. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfae271
BibTeX
@article{Dieter2025,
author = {Dieter, Rebecca A and Mattoo, Aprajita and Hotchkis, Perry and Jaffe, Ian S and Weldon, Elaina P and Berger, Jonathan C and Ali, Nicole M and Montgomery, Robert A and Lonze, Bonnie E},
title = {Prophylactic 2-week glecaprevir/pibrentasvir in hepatitis C positive-to-negative kidney transplantation},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
doi = {10.1093/ndt/gfae271}
}
EUVIMED